Sanofi-Aventis - Biotech Market Share Report

Sanofi-Aventis market share report graphic featuring Sanofi and Lantus logosCompany: Sanofi-Aventis
2007 Sales: $3.2 billion
Market share: 4.3%
CAGR: 37.7%

What they have: Sanofi's top-selling biotech blockbuster is Lantus, a Type 1 and 2 diabetes treatment. The company also markets a host of vaccines through Sanofi Pasteur, the vaccine division of Sanofi-Aventis.

What to look for: Currently, only 10 percent of the drugs Sanofi makes are biologics; in an interview, Senior Vice President, Scientific and Medical Affairs Mark Cluzel said the company wants to boost that number to 20 or 30 percent by 2012. Sanofi is collaborating with Regeneron on its drug Aflibercept (VEGF Trap), a cancer drug in late-stage trials for prostate and lung cancer.

Sanofi-Aventis - Biotech Market Share Report
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.